XML 86 R73.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Events (Details) - USD ($)
 1 Months Ended 12 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Jan. 31, 2022
Subsequent Events (Details) [Line Items]      
Terms of agreement, description   In accordance with the terms of the Agreement, the Company shall pay BioLite (i) milestone payments of up to $100 million in cash and equity of the Company or equity securities owned by it at various stages on a schedule dictated by BioLite’s achievements of certain milestones, as set forth in the Agreement (the “Milestone Payments”) and (ii) a royalty payment equal to 5% of net sales of the drug products when ABV-1501 is approved for sale in the licensed territories.  
Milestone payment, description   According to the Agreement, after Phase II clinical trials are completed, 15% of the Milestone Payment becomes due and shall be paid in two stages: (i) 5% no later than December 31, 2021 (the “December 2021 Payment”) and (ii) 10% no later than December 31, 2022. On February 12, 2022, the Company’s Board of Directors determined that the December 2021 Payment, which is equal to $5,000,000, shall be paid via the cancellation of certain outstanding debt, in the amount of $5,000,000, that BioLite owes the Company as of December 31, 2021.  
Subsequent Event [Member]      
Subsequent Events (Details) [Line Items]      
Aggregated shares of common stock     1,306,007
Additional shares of common stock 75,000    
Consulting and advisory services $ 15,000